The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in
Sponsorship statement:
Funding for this educational activity has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found below:
  • Sponsored by Pfizer Limited. Pfizer has had no involvement or influence over the content of this educational material.
  • This activity has been funded by Bayer plc. through a reactive sponsorship. Bayer plc. had no involvement with the development of this material.
Pfizer_Logo_Color_CMYK
Logo_Bayer

Signs and symptoms of amyloidosis – red flags for cardiologists

24 October 2025
Available for 1 CPD point(s)

Masterclass

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Effective treatment of cardiac amyloidosis is dependent on early diagnosis; it is therefore important that clinicians have a high index of suspicion for the condition in their patients. Dr Josephine Mansell from the National Amyloidosis Centre outlines the “red flag” signs and symptoms that cardiologists, nurses or other healthcare professionals may observe in their patients, and which should prompt consideration of referral for a full diagnostic workup.
Learning objectives:
  • To recognise the signs and symptoms of transthyretin (ATTR) and light-chain (AL) amyloidosis
  • To understand which patients should be considered at risk of potentially having amyloidosis, and in whom these red flag symptoms should be assessed
Speakers:

Dr Josephine Mansell Clinical Research Fellow
Angelique Smit Lead Clinical and Research Nurse

Categories

Tags

© 2025 Medinews Cardiology Ltd, a wholly-owned subsidiary of OmniaMed Communications Ltd   |   Privacy & cookies policy   |   Terms & conditions

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.